| Autor: |
Flotte Terence R, Maier Steven F, Hammack Sayamwong E, Wieseler-Frank Julie, Spataro Leah, Chacur Marucia, Cruz Pedro E, Langer Stephen J, Sloane Evan M, Milligan Erin D, Forsayeth John R, Leinwand Leslie A, Chavez Raymond, Watkins Linda R |
| Jazyk: |
angličtina |
| Rok vydání: |
2005 |
| Předmět: |
|
| Zdroj: |
Molecular Pain, Vol 1, Iss 1, p 9 (2005) |
| Druh dokumentu: |
article |
| ISSN: |
1744-8069 |
| DOI: |
10.1186/1744-8069-1-9 |
| Popis: |
Abstract Despite many decades of drug development, effective therapies for neuropathic pain remain elusive. The recent recognition of spinal cord glia and glial pro-inflammatory cytokines as important contributors to neuropathic pain suggests an alternative therapeutic strategy; that is, targeting glial activation or its downstream consequences. While several glial-selective drugs have been successful in controlling neuropathic pain in animal models, none are optimal for human use. Thus the aim of the present studies was to explore a novel approach for controlling neuropathic pain. Here, an adeno-associated viral (serotype II; AAV2) vector was created that encodes the anti-inflammatory cytokine, interleukin-10 (IL-10). This anti-inflammatory cytokine is known to suppress the production of pro-inflammatory cytokines. Upon intrathecal administration, this novel AAV2-IL-10 vector was successful in transiently preventing and reversing neuropathic pain. Intrathecal administration of an AAV2 vector encoding beta-galactosidase revealed that AAV2 preferentially infects meningeal cells surrounding the CSF space. Taken together, these data provide initial support that intrathecal gene therapy to drive the production of IL-10 may prove to be an efficacious treatment for neuropathic pain. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
